Last reviewed 2026-05-20 · How we verify

Torasemide (Diuver)

Society of Specialists in Heart Failure · FDA-approved active Small molecule ✓ Verified May 2026

Torasemide (Diuver) is a Loop diuretic Small molecule drug developed by Society of Specialists in Heart Failure. It is currently FDA-approved for Edema associated with congestive heart failure, Hypertension, Edema associated with renal disease.

Torasemide is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending limb of the loop of Henle, promoting fluid and electrolyte excretion.

Torasemide, also known as Diuver, is used to treat conditions such as Arterial Hypertension and Chronic Heart Failure. It is available in prolonged release formulations, including Britomar, and has been studied in clinical trials, including the investigator-initiated study NCT02087332.

At a glance

Generic name	Torasemide (Diuver)
Sponsor	Society of Specialists in Heart Failure
Drug class	Loop diuretic
Target	Na-K-2Cl cotransporter (NKCC2)
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved

Mechanism of action

Torasemide blocks the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, preventing reabsorption of sodium, potassium, and chloride. This increases urine output and reduces fluid overload in the body. It is commonly used to manage edema and hypertension associated with heart failure, renal disease, and hepatic cirrhosis.

Approved indications

Edema associated with congestive heart failure
Hypertension
Edema associated with renal disease
Edema associated with hepatic cirrhosis

Common side effects

Hypokalemia
Hyperuricemia
Ototoxicity (at high doses)
Dehydration
Hypotension
Hyperglycemia

Key clinical trials

Investigator Initiated Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics. (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Torasemide (Diuver) CI brief — competitive landscape report
Torasemide (Diuver) updates RSS · CI watch RSS
Society of Specialists in Heart Failure portfolio CI

Frequently asked questions about Torasemide (Diuver)

What is Torasemide (Diuver)?

Torasemide (Diuver) is a Loop diuretic drug developed by Society of Specialists in Heart Failure, indicated for Edema associated with congestive heart failure, Hypertension, Edema associated with renal disease.

How does Torasemide (Diuver) work?

Torasemide is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending limb of the loop of Henle, promoting fluid and electrolyte excretion.

What is Torasemide (Diuver) used for?

Torasemide (Diuver) is indicated for Edema associated with congestive heart failure, Hypertension, Edema associated with renal disease, Edema associated with hepatic cirrhosis.

Who makes Torasemide (Diuver)?

Torasemide (Diuver) is developed and marketed by Society of Specialists in Heart Failure (see full Society of Specialists in Heart Failure pipeline at /company/society-of-specialists-in-heart-failure).

What drug class is Torasemide (Diuver) in?

Torasemide (Diuver) belongs to the Loop diuretic class. See all Loop diuretic drugs at /class/loop-diuretic.

What development phase is Torasemide (Diuver) in?

Torasemide (Diuver) is FDA-approved (marketed).

What are the side effects of Torasemide (Diuver)?

Common side effects of Torasemide (Diuver) include Hypokalemia, Hyperuricemia, Ototoxicity (at high doses), Dehydration, Hypotension, Hyperglycemia.

What does Torasemide (Diuver) target?

Torasemide (Diuver) targets Na-K-2Cl cotransporter (NKCC2) and is a Loop diuretic.

Drug class: All Loop diuretic drugs
Target: All drugs targeting Na-K-2Cl cotransporter (NKCC2)
Manufacturer: Society of Specialists in Heart Failure — full pipeline
Therapeutic area: All drugs in Cardiovascular
Indication: Drugs for Edema associated with congestive heart failure
Indication: Drugs for Hypertension
Indication: Drugs for Edema associated with renal disease

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing